What You Should Know:
– Mayo Clinic and Numares Health have expanded their collaboration recently to develop AI-enabled diagnostic testing that is more accurate and reliable than current U.S. tests for patients with chronic diseases, including kidney, cardiovascular, liver and neurologic conditions.
– The expanded collaboration builds on Mayo Clinic’s clinical research support for Numares Health to include an innovative convertible equity investment.
AI-Enabled Diagnostic Testing
Numares is a German healthcare diagnostics company that develops advanced tests to aid in diagnosis and measurement of disease progression by applying machine learning to metabolomics and other biomarkers. Numares is developing improved diagnostic testing designed to give physicians a better tool to care for their patients with conditions related to metabolic dysfunction, such as chronic kidney, liver and cardiac diseases. These assessments also may allow for early intervention to slow disease progression.
Two Numares tests are expected to gain FDA 510(k) approval early next year, one assessing kidney function (AXINON® GFR(NMR) test) and one measuring cardiac risk (AXINON® lipoFIT® test). Enabled by machine learning, this innovative testing modality being researched uses distinct and transparent algorithms combining multiple #biomarkers to measure disease progression more accurately in patients with chronic diseases.
“This significant expansion of our long-standing collaboration with Mayo Clinic has brought us one step closer to our shared goal of improving patient care. The new investment accelerates our development pipeline and drives research collaborations that fulfill critical unmet medical needs with new clinical utility. With the additional investment, we’ve enhanced our ability to target our focus on delivering this patient care technology to U.S. physicians as an improved diagnostic tool for their use,” said Winton Gibbons, Numares chief executive officer.
